Journal articles: 'Anticancer'

1

Ammazzalorso, Alessandra, and Marialuigia Fantacuzzi. "Anticancer Inhibitors." Molecules 27, no. 14 (July 21, 2022): 4650. http://dx.doi.org/10.3390/molecules27144650.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dove, Alan. "Anticancer verotoxin." Nature Biotechnology 17, no. 8 (August 1999): 738. http://dx.doi.org/10.1038/11646.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Reese, David M. "Anticancer drugs." Nature 378, no. 6557 (December 1995): 532. http://dx.doi.org/10.1038/378532c0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Worland, PhD, Peter J., Gary S. Gray, PhD, Mark Rolfe, PhD, Karen Gray, PhD, and Jeffrey S. Ross, MD. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (April 1, 2003): 472–85. http://dx.doi.org/10.1309/y6lp-c0lr-726l-9dx9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ross, Jeffrey S., Karen Gray, Gary S. Gray, Peter J. Worland, and Mark Rolfe. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (April 2003): 472–85. http://dx.doi.org/10.1309/y6lpc0lr726l9dx9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

LeBrasseur, Nicole. "Anticancer lubrication." Journal of Cell Biology 156, no. 6 (March 11, 2002): 940. http://dx.doi.org/10.1083/jcb1566rr1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

VanHook, A. M. "Anticancer Cocktails." Science Signaling 7, no. 347 (October 14, 2014): ec284-ec284. http://dx.doi.org/10.1126/scisignal.aaa0425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

ROUHI, MAUREEN. "ANTICANCER VACCINE." Chemical & Engineering News 75, no. 3 (January 20, 1997): 8. http://dx.doi.org/10.1021/cen-v075n003.p008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bergman, Philip J. "Anticancer Vaccines." Veterinary Clinics of North America: Small Animal Practice 37, no. 6 (November 2007): 1111–19. http://dx.doi.org/10.1016/j.cvsm.2007.06.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bonetta, Laura. "Anticancer squirt." Nature Medicine 7, no. 8 (August 2001): 891. http://dx.doi.org/10.1038/90920.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Iqbal, Javed, Banzeer Ahsan Abbasi, Tariq Mahmood, Sobia Kanwal, Barkat Ali, Sayed Afzal Shah, and Ali Talha Khalil. "Plant-derived anticancer agents: A green anticancer approach." Asian Pacific Journal of Tropical Biomedicine 7, no. 12 (December 2017): 1129–50. http://dx.doi.org/10.1016/j.apjtb.2017.10.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, no. 1 (March 19, 2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.

Full text

Abstract:

Cancer is a state of uncontrolled proliferation and dedifferentiation of cells in any tissues or organs of the body. The incidence of cancer is rising alarmingly and is one of the leading causes of morbidity and mortality globally. Normal cell division is precisely a planned biological process controlled by regulatory genes and specific metabolic pathways. Exposure of normally functioning cells to carcinogens leads to mutations in the genes causing loss of control of cell division and transform into cancerous. Over a period of time, these cancer cells acquire more mutations; invade to adjoining tissues, escape the process of apoptosis and the cells become eternal. Breakaway parts of the cancer tissues / cells travel through the lymphatic and blood vessels and get deposited in other tissues / organs leading to metastasis, the spread of cancer.

APA, Harvard, Vancouver, ISO, and other styles

13

Li, Dong Hong, Jun Lin Diao, Ke Gui Yu, and Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs." Chinese Chemical Letters 18, no. 11 (November 2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Bousbaa, Hassan. "Novel Anticancer Strategies." Pharmaceutics 13, no. 2 (February 18, 2021): 275. http://dx.doi.org/10.3390/pharmaceutics13020275.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Siddiq, A., and V. Dembitsky. "Acetylenic Anticancer Agents." Anti-Cancer Agents in Medicinal Chemistry 8, no. 2 (February 1, 2008): 132–70. http://dx.doi.org/10.2174/187152008783497073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "New anticancer approaches." Inpharma Weekly &NA;, no. 884 (April 1993): 11. http://dx.doi.org/10.2165/00128413-199308840-00023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "New anticancer developments." Inpharma Weekly &NA;, no. 887 (May 1993): 14. http://dx.doi.org/10.2165/00128413-199308870-00035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ricupito, Alessia, Matteo Grioni, Arianna Calcinotto, and Matteo Bellone. "Boosting anticancer vaccines." OncoImmunology 2, no. 7 (July 2013): e25032. http://dx.doi.org/10.4161/onci.25032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Loadman, P. "Anticancer Drug Development." British Journal of Cancer 86, no. 10 (May 2002): 1665–66. http://dx.doi.org/10.1038/sj.bjc.6600309.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Tabares, Tyler, Todd Unmack, Mary Calys, and Lisa Stehno-Bittel. "New Anticancer Immunotherapies." Rehabilitation Oncology 37, no. 3 (July 2019): 128–37. http://dx.doi.org/10.1097/01.reo.0000000000000144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Drug Discovery 1, no. 7 (July 2002): 491–92. http://dx.doi.org/10.1038/nrd842.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Nencioni, A., F. Grünebach, F. Patrone, and P. Brossart. "Anticancer vaccination strategies." Annals of Oncology 15 (October 2004): iv153—iv160. http://dx.doi.org/10.1093/annonc/mdh920.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Mann, John. "Nature's anticancer agents." Nature 361, no. 6407 (January 1993): 21–22. http://dx.doi.org/10.1038/361021a0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Gabernet, G., A. T. Müller, J. A. Hiss, and G. Schneider. "Membranolytic anticancer peptides." MedChemComm 7, no. 12 (2016): 2232–45. http://dx.doi.org/10.1039/c6md00376a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Ades, Felipe, Dimitrios Zardavas, Philippe Aftimos, and Ahmad Awada. "Anticancer drug development." Current Opinion in Oncology 26, no. 3 (May 2014): 334–39. http://dx.doi.org/10.1097/cco.0000000000000076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Manus, Jean-Marie. "Brèves : Virothérapie anticancer." Revue Francophone des Laboratoires 2019, no. 510 (March 2019): 5. http://dx.doi.org/10.1016/s1773-035x(19)30174-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Caruso, Francesco, Miriam Rossi, and Claudio Pettinari. "Anticancer titanium agents." Expert Opinion on Therapeutic Patents 11, no. 6 (June 2001): 969–79. http://dx.doi.org/10.1517/13543776.11.6.969.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Murray, Samuel, and Helena Linardou. "Therapeutic anticancer antibodies." Expert Opinion on Therapeutic Patents 13, no. 2 (February 2003): 177–222. http://dx.doi.org/10.1517/13543776.13.2.177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Cancer 2, no. 9 (September 2002): 645–46. http://dx.doi.org/10.1038/nrc900.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Takigawa, Nagio. "Cytotoxic Anticancer Agents." Annals of Oncology 30 (October 2019): vi57. http://dx.doi.org/10.1093/annonc/mdz333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Toca-Muñoz, M., B. Mora-Rodríguez, A. Luna-Higuera, E. Valverde Alcalá, and I. M. Muñoz-Castillo. "Targeted anticancer treatments." European Journal of Hospital Pharmacy 19, no. 2 (March 12, 2012): 185.1–185. http://dx.doi.org/10.1136/ejhpharm-2012-000074.264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Tonini, Giuseppe, Bruno Vincenzi, and Daniele Santini. "Bisphosphonate anticancer activity." Expert Opinion on Pharmacotherapy 12, no. 5 (March 9, 2011): 681–83. http://dx.doi.org/10.1517/14656566.2011.543279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Tong, Rong, and Jianjun Cheng. "Anticancer Polymeric Nanomedicines." Polymer Reviews 47, no. 3 (July 2007): 345–81. http://dx.doi.org/10.1080/15583720701455079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Bibby, M. C. "Combretastatin anticancer drugs." Drugs of the Future 27, no. 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gasser, Gilles, Ingo Ott, and Nils Metzler-Nolte. "Organometallic Anticancer Compounds." Journal of Medicinal Chemistry 54, no. 1 (January 13, 2011): 3–25. http://dx.doi.org/10.1021/jm100020w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Sikic, B. I. "Anticancer Drug Discovery." JNCI Journal of the National Cancer Institute 83, no. 11 (June 5, 1991): 738–40. http://dx.doi.org/10.1093/jnci/83.11.738.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Tabassum, Yasmeen, and Dr Deoraj Sharma. "Anticancer medicinal plants." International Journal of Pharmacognosy and Life Science 3, no. 2 (July 1, 2022): 46–53. http://dx.doi.org/10.33545/27072827.2022.v3.i2a.62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Dąbrowska, Krystyna, Zuzanna Kaźmierczak, Joanna Majewska, Paulina Miernikiewicz, Agnieszka Piotrowicz, Joanna Wietrzyk, Dorota Lecion, et al. "Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment." Future Microbiology 9, no. 7 (July 2014): 861–69. http://dx.doi.org/10.2217/fmb.14.50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis." Blood 136, Supplement 1 (November 5, 2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.

Full text

Abstract:

Introduction Anticancer treatments has been changing since decades, evolving from chemotherapy (platinum salts) to recent check-point inhibitors. Nausea, vomiting and diarrhoea are common adverse events of anticancer drugs, despites the fact that some supportive care drugs can manage these adverse events. Gastro-intestinal (GI) disorders/toxicities are also important. Such as gastric/duodenal ulcer, gastritis, stomatitis, colitis, esophagitis... Cancer-associated-thrombosis (CAT) patients were also reported to be exposed to such GI disorders/toxicities and several publications recommended to consider these GI disorders/toxicities when choosing an anticoagulant in CAT (Carrier M. Curr Oncol 2018; Moik F. ESMO Open 2020). However, little is known about the nature of the anticancer drugs that CAT patients are receiving. The aim of this work was to check all the anticancer's SmPCs (Summary of Product Characteristics) on the EMA website for GI disorders. Methods All SmPCs of anticancer drugs indicated for lung cancer were checked on the EMA website. All adverse events regarding GI disorders/toxicities were collected. The frequency of adverse events used was the following: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000). However, it was decided to mainly focus on very common and common ones. Old anticancer drugs SmPCs (platinium salts...) were checked on electronic medicines compendium (medicines.org.uk), because these old SmPCs are not always available on the EMA website. Generics, biosimilars and drugs without a licence were excluded. Results Twenty-eight anticancer drugs were identified with a mix of traditional chemotherapies (platinum salts...), tyrosine kinase inhibitors (nib) and monoclonal antibodies (mab). Among these 28 anticancer drugs, 26 had at least one very common/common GI disorders/toxicities. Obviously, vomiting (82.1%) and diarrhoea (89.3%) are very well-known, but it was interesting to see that many anticancer drugs were associated with other very common/common GI toxicities such as stomatitis (71.4%) and colitis (10.7%). Additionally, several drugs (35.7%) were exposing to GI bleeding and/or GI perforation but these last adverse events were less common. Unfortunately, the SmPCs did not include data about the GI profile of the patients during the trials. Conclusion Monreal M et al reported in 1991 that acute gastroduodenal lesion was found in 21% of patients with venous thromboembolism, but there are no dedicated study about the incidence of GI disorders in CAT patients. This work reported that GI disorders/toxicities were common in anticancer drug's SmPCs. Consequently, it is important to be aware of this before initiating an anticoagulant treatment. However, this work had limitations. Indeed, these adverse events were reported in the SmPCs, based mainly on cancer trials and not on CAT trials. Furthermore, clinical trials and SmPCs may not always reflect the real clinical setting. Finally, lung cancer patients are usually receiving anticancer regimens that include several anticancer drugs, so the potential impact of GI disorders/toxicities from 2 or 3 anticancer drugs on a single patients could be greater. Nevertheless, it sounds reasonable to check for GI disorders/toxicities risks in order to initiate an adequate anticoagulant treatment in CAT patients and during follow-up. Disclosures Janus: Guerbet:Research Funding;B-Braun:Honoraria;LEO Pharma A/S:Current Employment, Honoraria;Fresenius Medical Care:Honoraria;Amgen:Honoraria, Research Funding;TEVA:Research Funding;Daichii-Sankyo:Honoraria, Research Funding;Roche:Honoraria, Research Funding;Vifor Pharma:Honoraria, Research Funding;Gilead:Honoraria, Research Funding;Novartis:Honoraria;Pierre Fabre Oncology:Research Funding;Bayer:Honoraria, Research Funding;Pfizer:Consultancy, Honoraria;IPSEN:Honoraria.

APA, Harvard, Vancouver, ISO, and other styles

40

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K, and Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS." Indian Research Journal of Pharmacy and Science 5, no. 1 (March 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

AFFI, Sopi Thomas, Doh SORO, Souleymane COULIBALY, Bibata KONATE, and Nahossé ZIAO. "Modeling anticancer pharmacophore based on inhibition of HDAC7." SDRP Journal of Computational Chemistry & Molecular Modeling 5, no. 3 (2021): 657–63. http://dx.doi.org/10.25177/jccmm.5.3.ra.10776.

Full text

Abstract:

Histone deacetylases (HDACs) are the target inhibition enzymes in cancer treatment via chemotherapy. Application of this therapeutic technique requires the use of drugs whose side effects are reduced and tiny with necessary safety. In this study, the methods and tools of pharmacophore modeling were used to investigate ten molecules known for their anticancer properties. Particular attention has been given to pinpoint a promising anti-cancer pharmacophore in order to lead new effective inhibitors. Using Discovery Studio 2.5 software, the ten compounds were docked within the active site of the HDAC7 enzyme. Analysis of the binding characteristics of all the compounds collected and tested in the model resulted in the characteristics produced by the 3D pharmacophore of the selected hypothesis. This led to note that the efficiency of any HDAC enzyme inhibitor was related to the characteristics of the designed pharmacophore. At the end, the pharmacophore hypothesis used here was presented as a useful basis for the development of anticancer compounds. Keywords: Pharmacophore, 3c0z, HDAC7, QSAR

APA, Harvard, Vancouver, ISO, and other styles

42

SB, Patil. "Anticancer Potential of Novel Pyrimidine Analogs: Recent Updates." Medicinal and Analytical Chemistry International Journal 8, no. 1 (January 31, 2024): 1–6. http://dx.doi.org/10.23880/macij-16000189.

Full text

Abstract:

Pyrimidine, having two nitrogen atoms, looks like pyridine and benzene. In nature, pyrimidine is present in different forms, such as the bases of DNA and RNA. Due to its structure, various kinds of biological activity have been observed. The substituted and fused pyrimidine derivatives were chemically synthesized and showed anti-cancer potential against cancer cell lines (SW480, A549, CCRF-CEM, THP-1, HepG2, HCT-116, PC3, Huh-7, CNE-2, MGC-803, and MDA-MB-435). Based on the experimental results, the substituted pyrimidines and fused derivatives showed remarkably enhanced anticancer activity, which may be due to the presence of Cl, F, Br, CH3O, aryl urea, indolyl pyrimidine, thienopyrimidine, benzyl amino pyrimidine and the pyrimidine moiety. In this article, recent anticancer research findings were highlighted

APA, Harvard, Vancouver, ISO, and other styles

43

Pluta, Krystian, Małgorzata Jeleń, Beata Morak-Młodawska, Michał Zimecki, Jolanta Artym, and Maja Kocięba. "Anticancer activity of newly synthesized azaphenothiazines from NCI’s anticancer screening bank." Pharmacological Reports 62, no. 2 (March 2010): 319–32. http://dx.doi.org/10.1016/s1734-1140(10)70272-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kim, Byungkuk, Eunsun Lee, Yerang Kim, Sanga Park, Gilson Khang, and Dongwon Lee. "Dual Acid-Responsive Micelle-Forming Anticancer Polymers as New Anticancer Therapeutics." Advanced Functional Materials 23, no. 40 (July 19, 2013): 5091–97. http://dx.doi.org/10.1002/adfm201300871.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Tao, Hongyu, Ling Zuo, Huanli Xu, Cong Li, Gan Qiao, Mingyue Guo, and Xiukun Lin. "Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years." Recent Patents on Anti-Cancer Drug Discovery 15, no. 1 (May 13, 2020): 2–13. http://dx.doi.org/10.2174/1574892815666200131120618.

Full text

Abstract:

Background: In recent years, many novel alkaloids with anticancer activity have been found in China, and some of them are promising for developing as anticancer agents. Objective: This review aims to provide a comprehensive overview of the information about alkaloid anticancer agents disclosed in Chinese patents, and discusses their potential to be developed as anticancer drugs used clinically. Methods: Anticancer alkaloids disclosed in Chinese patents in recent 5 years were presented according to their mode of actions. Their study results published on PubMed, and SciDirect databases were presented. Results: More than one hundred anticancer alkaloids were disclosed in Chinese patents and their mode of action referred to arresting cell cycle, inhibiting protein kinases, affecting DNA synthesis and p53 expression, etc. Conclusion: Many newly found alkaloids displayed potent anticancer activity both in vitro and in vivo, and some of the anticancer alkaloids acted as protein kinase inhibitors or CDK inhibitors possess the potential for developing as novel anticancer agents.

APA, Harvard, Vancouver, ISO, and other styles

46

Jiso, Apisada, Phisit Khemawoot, Pinnakarn Techapichetvanich, Sutinee Soopairin, Kittiphong Phoemsap, Panrawee Damrongsakul, Supakit Wongwiwatthananukit, and Pornpun Vivithanaporn. "Drug-Herb Interactions among Thai Herbs and Anticancer Drugs: A Scoping Review." Pharmaceuticals 15, no. 2 (January 26, 2022): 146. http://dx.doi.org/10.3390/ph15020146.

Full text

Abstract:

More than half of Thai patients with cancer take herbal preparations while receiving anticancer therapy. There is no systematic or scoping review on interactions between anticancer drugs and Thai herbs, although several research articles have that Thai herbs inhibit cytochrome P450 (CYP) or efflux transporter. Therefore, we gathered and integrated information related to the interactions between anticancer drugs and Thai herbs. Fifty-two anticancer drugs from the 2020 Thailand National List of Essential Medicines and 75 herbs from the 2020 Thai Herbal Pharmacopoeia were selected to determine potential anticancer drug–herb interactions. The pharmacological profiles of the selected anticancer drugs were reviewed and matched with the herbal pharmacological activities to determine possible interactions. A large number of potential anticancer drug–herb interactions were found; the majority involved CYP inhibition. Efflux transporter inhibition and enzyme induction were also found, which could interfere with the pharmacokinetic profiles of anticancer drugs. However, there is limited knowledge on the pharmacodynamic interactions between anticancer drugs and Thai herbs. Therefore, further research is warranted. Information regarding interactions between anticancer drugs and Thai herbs should provide as a useful resource to healthcare professionals in daily practice. It could enable the prediction of possible anticancer drug–herb interactions and could be used to optimize cancer therapy outcomes.

APA, Harvard, Vancouver, ISO, and other styles

47

Ogo, Ayako, Sachi Miyake, Hisako Kubota, Masaharu Higashida, Hideo Matsumoto, Fusako Teramoto, and Toshihiro Hirai. "Synergistic Effect of Eicosapentaenoic Acid on Antiproliferative Action of Anticancer Drugs in a Cancer Cell Line Model." Annals of Nutrition and Metabolism 71, no. 3-4 (2017): 247–52. http://dx.doi.org/10.1159/000484618.

Full text

Abstract:

Background/Aims: It has been found experimentally and clinically that eicosapentaenoic acid (EPA) exerts an anticancer effect and that it has a minimal adverse event profile relative to other anticancer drugs. Any synergy between EPA and other anticancer drugs could be of therapeutic relevance, especially in elderly or high-risk patients. Therefore, we investigated the synergism between anticancer drugs and EPA experimentally. Methods: EPA was coadministered in vitro with various anticancer drugs (paclitaxel, docetaxel, 5-fluorouracil and cis-diamminedichloridoplatinum[II]) to TE-1 cells, which were derived from human esophageal cancer tumors. Cell proliferation was measured by the water soluble tetrazolium-1 method. Result: Sub-threshold concentrations of EPA, which alone produced no anticancer effect, caused a synergistic suppressive effect on TE-1 cell proliferation when combined with other anticancer agents. Conclusion: Coadministration of EPA with other anticancer drugs may represent a new therapeutic paradigm offering a reduced side effect profile.

APA, Harvard, Vancouver, ISO, and other styles

48

Chen, Qian, Jing Wu, Xiang Li, Ziyi Ye, Hailong Yang, and Lixian Mu. "Amphibian-Derived Natural Anticancer Peptides and Proteins: Mechanism of Action, Application Strategies, and Prospects." International Journal of Molecular Sciences 24, no. 18 (September 12, 2023): 13985. http://dx.doi.org/10.3390/ijms241813985.

Full text

Abstract:

Cancer is one of the major diseases that seriously threaten human life. Traditional anticancer therapies have achieved remarkable efficacy but have also some unavoidable side effects. Therefore, more and more research focuses on highly effective and less-toxic anticancer substances of natural origin. Amphibian skin is rich in active substances such as biogenic amines, alkaloids, alcohols, esters, peptides, and proteins, which play a role in various aspects such as anti-inflammatory, immunomodulatory, and anticancer functions, and are one of the critical sources of anticancer substances. Currently, a range of natural anticancer substances are known from various amphibians. This paper aims to review the physicochemical properties, anticancer mechanisms, and potential applications of these peptides and proteins to advance the identification and therapeutic use of natural anticancer agents.

APA, Harvard, Vancouver, ISO, and other styles

49

Palmieri, Vittorio, Maria Teresa Vietri, Andrea Montalto, Andrea Montisci, Francesco Donatelli, Enrico Coscioni, and Claudio Napoli. "Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs." Cancers 15, no. 8 (April 10, 2023): 2224. http://dx.doi.org/10.3390/cancers15082224.

Full text

Abstract:

Background: Anticancer treatments are improving the prognosis of patients fighting cancer. However, anticancer treatments may also increase the cardiovascular (CV) risk by increasing metabolic disorders. Atherosclerosis and atherothrombosis related to anticancer treatments may lead to ischemic heart disease (IHD), while direct cardiac toxicity may induce non-ischemic heart disease. Moreover, valvular heart disease (VHD), aortic syndromes (AoS), and advanced heart failure (HF) associated with CV risk factors and preclinical CV disease as well as with chronic inflammation and endothelial dysfunction may also occur in survivors of anti-carcer treatments. Methods: Public electronic libraries have been searched systematically looking at cardiotoxicity, cardioprotection, CV risk and disease, and prognosis after cardiac surgery in survivors of anticancer treatments. Results: CV risk factors and disease may not be infrequent among survivors of anticancer treatments. As cardiotoxicity of established anticancer treatments has been investigated and is frequently irreversible, cardiotoxicity associated with novel treatments appears to be more frequently reversible, but also potentially synergic. Small reports suggest that drugs preventing HF in the general population may be effective also among survivors of anticancer treatments, so that CV risk factors and disease, and chronic inflammation, may lead to indication to cardiac surgery in survivors of anticancer treatments. There is a lack of substantial data on whether current risk scores are efficient to predict prognosis after cardiac surgery in survivors of anticancer treatments, and to guide tailored decision-making. IHD is the most common condition requiring cardiac surgery among survivors of anticancer treatments. Primary VHD is mostly related to a history of radiation therapy. No specific reports exist on AoS in survivors of anticancer treatments. Conclusions: It is unclear whether interventions to dominate cancer- and anticancer treatment-related metabolic syndromes, chronic inflammation, and endothelial dysfunction, leading to IHD, nonIHD, VHD, HF, and AoS, are as effective in survivors of anticancer treatments as in the general population. When CV diseases require cardiac surgery, survivors of anticancer treatments may be a population at specifically elevated risk, rather than affected by a specific risk factor.

APA, Harvard, Vancouver, ISO, and other styles

50

Park, Hee-Sook. "Prospect of Anticancer Therapy." Cancer Research and Treatment 36, no. 2 (2004): 100. http://dx.doi.org/10.4143/crt.2004.36.2.100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Anticancer'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles